Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cumberland Pharmaceuticals (CPIX) EBITDA Margin (2016 - 2025)

Cumberland Pharmaceuticals' EBITDA Margin history spans 16 years, with the latest figure at 10.02% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 763.0% year-over-year to 10.02%; the TTM value through Dec 2025 reached 6.27%, up 1072.0%, while the annual FY2025 figure was 3.08%, 1391.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 10.02% at Cumberland Pharmaceuticals, up from 23.7% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 11.03% in Q1 2025 and bottomed at 52.33% in Q4 2021.
  • The 5-year median for EBITDA Margin is 16.6% (2023), against an average of 14.78%.
  • The largest annual shift saw EBITDA Margin tumbled -3532bps in 2021 before it skyrocketed 3303bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 52.33% in 2021, then skyrocketed by 52bps to 24.97% in 2022, then increased by 26bps to 18.51% in 2023, then increased by 5bps to 17.65% in 2024, then surged by 43bps to 10.02% in 2025.
  • Per Business Quant, the three most recent readings for CPIX's EBITDA Margin are 10.02% (Q4 2025), 23.7% (Q3 2025), and 6.9% (Q2 2025).